Recently, Smith et al. demonstrated that pharmacological activation of PP2A inhibited FLT3-mediated growth and survival of AML cells, and suggested that PP2A activation may be a therapeutic strategy for treating FLT3-driven malignancies [11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.